Galectin Therapeutics Inc.
看多

Cross above 200 day moving average, cup and handle

57
GALT cross above 200 day moving average after a lengthy period of consolidation in tightening trading range.

Cup and handle.

Leading drug in a pivotal clinical trial for advanced cirrhosis.

  • High insider ownership of shares
  • Recent hiring of a renowned liver expert VP from big pharma

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。